Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
September 7, 2021
Assignee:
CELVERUM INC.
Inventors:
David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
Abstract: An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells are infected ex vivo with a virus that modulates the expression of a plurality of endogenous immune regulatory molecules to increase the immunogenicity of the hematopoietic cancer cells.
Type:
Grant
Filed:
November 8, 2012
Date of Patent:
April 18, 2017
Assignee:
Celverum Inc.
Inventors:
David Conrad, John Cameron Bell, Harry Atkins